Sionna Therapeutics secures $111 million in Series B funding

Sionna Therapeutics is a Boston, MA-based life sciences company developing differentiated treatments for cystic fibrosis (CF), dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF) by normalizing CFTR function, a key protein associated with CF disease progression. Recently announced that it has received US$111 million in Series B financing, led by OrbiMed, Atlas Venture, RA Capital Management, TPG’s The Rise Fund, Q Healthcare Holdings, and T. Rowe Price.

This article is reproduced from:
This site is for inclusion only, and the copyright belongs to the original author.

Leave a Comment